

## Web References –

Werner et al., Anogenital warts and other HPV-associated anogenital lesions in the HIV-positive patient: a systematic review and meta-analysis of the efficacy and safety of interventions assessed in controlled clinical trials

- w1. Giuliano AR, Lee JH, Fulp W, et al. Incidence and clearance of genital human papillomavirus infection in men (HIM): a cohort study.[Erratum appears in *Lancet*. 2011 Jun 11;377(9782):2006]. *Lancet*. 2011;377(9769):932-40. DOI [http://dx.doi.org/10.1016/S0140-6736\(10\)62342-2](http://dx.doi.org/10.1016/S0140-6736(10)62342-2).
- w2. Nyitray A, Nielson CM, Harris RB, et al. Prevalence of and risk factors for anal human papillomavirus infection in heterosexual men. *J Infect Dis*. 2008;197(12):1676-84. DOI 10.1086/588145.
- w3. Dona MG, Benevolo M, Vocaturo A, et al. Anal cytological abnormalities and epidemiological correlates among men who have sex with men at risk for HIV-1 infection. *BMC Cancer*. 2012;12. DOI 10.1186/1471-2407-12-476.
- w4. Damay A, Fabre J, Costes V, et al. Human Papillomavirus (HPV) Prevalence and Type Distribution, and HPV-Associated Cytological Abnormalities in Anal Specimens From Men Infected With HIV Who Have Sex with Men. *J Med Virol*. 2010;82(4):592-6. DOI 10.1002/Jmv.21732.
- w5. Fenton KA, Lowndes CM, Network E. Recent trends in the epidemiology of sexually transmitted infections in the European Union. *Sex Transm Dis*. 2004;80(4):255-63. DOI 10.1136/sti.2004.009415.
- w6. Hillemanns P, Breugelmans JG, Giesecking F, et al. Estimation of the incidence of genital warts and the cost of illness in Germany: a cross-sectional study. *BMC Infect Dis*. 2008;8:76. DOI 10.1186/1471-2334-8-76.
- w7. Petry KU, Luyten A, Justus A, et al. Prevalence of low-risk HPV types and genital warts in women born 1988/89 or 1983/84 - results of WOLVES, a population-based epidemiological study in Wolfsburg, Germany. *BMC Infect Dis*. 2012;12. DOI 10.1186/1471-2334-12-367.
- w8. Kraut AA, Schink T, Schulze-Rath R, et al. Incidence of anogenital warts in Germany: a population-based cohort study. *BMC Infect Dis*. 2010;10. DOI 10.1186/1471-2334-10-360.
- w9. Munk C, Nielsen A, Liaw KL, et al. Genital warts in men: a large population-based cross-sectional survey of Danish men. *Sex Transm Infect*. 2012;88(8):640-4. DOI 10.1136/sextrans-2012-050512.
- w10. Insinga RP, Dasbach EJ, Myers ER. The health and economic burden of genital warts in a set of private health plans in the United States. *Clin Infect Dis*. 2003;36(11):1397-403. DOI 10.1086/375074.
- w11. Baio G, Capone A, Marcellusi A, et al. Economic Burden of Human Papillomavirus-Related Diseases in Italy. *PLoS One*. 2012;7(11). DOI 10.1371/journal.pone.0049699.
- w12. Lanitis T, Carroll S, O'Mahony C, et al. The cost of managing genital warts in the UK. *Int J STD AIDS*. 2012;23(3):189-94. DOI 10.1258/ijsa.2011.011218.
- w13. Castellsague X, Cohet C, Puig-Tintore LM, et al. Epidemiology and cost of treatment of genital warts in Spain. *Eur J Public Health*. 2009;19(1):106-10. DOI 10.1093/eurpub/ckn127.
- w14. Olsen J, Jorgensen TR, Kofoed K, et al. Incidence and cost of anal, penile, vaginal and vulvar cancer in Denmark. *BMC Public Health*. 2012;12. DOI 10.1186/1471-2458-12-1082.
- w15. Preaud E, LARGERON N. Economic burden of non-cervical cancers attributable to human papillomavirus: a European scoping review. *J Med Econ*. 2013;16(6):763-76. DOI 10.3111/13696998.2013.793691.
- w16. Dominiak-Felden G, Cohet C, Atrux-Tallau S, et al. Impact of human papillomavirus-related genital diseases on quality of life and psychosocial wellbeing: results of an

- observational, health-related quality of life study in the UK. *BMC Public Health*. 2013;13:1065. DOI 10.1186/1471-2458-13-1065.
- w17. Drolet M, Brisson M, Maunsell E, et al. The Impact of Anogenital Warts on Health-Related Quality of Life: A 6-Month Prospective Study. *Sex Transm Dis*. 2011;38(10):949-56. DOI 10.1097/OIq.0b013e3182215512.
- w18. Senecal M, Brisson M, Maunsell E, et al. Loss of quality of life associated with genital warts: baseline analyses from a prospective study. *Sex Transm Infect*. 2011;87(3):209-15. DOI 10.1136/sti.2009.039982.
- w19. Shi JF, Kang DJ, Qi SZ, et al. Impact of genital warts on health related quality of life in men and women in mainland China: a multicenter hospital-based cross-sectional study. *BMC Public Health*. 2012;12:153. DOI 10.1186/1471-2458-12-153.
- w20. Woodhall S, Ramsey T, Cai C, et al. Estimation of the impact of genital warts on health-related quality of life. *Sex Transm Infect*. 2008;84(3):161-6. DOI 10.1136/sti.2007.029512.
- w21. Woodhall SC, Jit M, Soldan K, et al. The impact of genital warts: loss of quality of life and cost of treatment in eight sexual health clinics in the UK. *Sex Transm Infect*. 2011;87(6):458-63. DOI 10.1136/sextrans-2011-050073.
- w22. Palefsky JM, Holly EA, Hogeboom CJ, et al. Virologic, immunologic, and clinical parameters in the incidence and progression of anal squamous intraepithelial lesions in HIV-positive and HIV-negative homosexual men. *J Acquir Immune Defic Syndr Hum Retrovirol*. 1998;17(4):314-9.
- w23. Watson AJM, Smith BB, Whitehead MR, et al. Malignant progression of anal intraepithelial neoplasia. *ANZ J Surg*. 2006;76(8):715-7. DOI 10.1111/j.1445-2197.2006.03837.x.
- w24. Frisch M, Biggar RJ, Goedert JJ. Human papillomavirus-associated cancers in patients with human immunodeficiency virus infection and acquired immunodeficiency syndrome. *J Natl Cancer Inst*. 2000;92(18):1500-10.
- w25. Palefsky JM, Holly EA, Ralston ML, et al. High incidence of anal high-grade squamous intra-epithelial lesions among HIV-positive and HIV-negative homosexual and bisexual men. *AIDS*. 1998;12(5):495-503. DOI 10.1097/00002030-199805000-00011.
- w26. Patel HS, Silver ARJ, Northover JMA. Anal cancer in renal transplant patients. *Int J Colorectal Dis*. 2007;22(1):1-5. DOI 10.1007/s00384-005-0023-3.
- w27. Kreuter A, Potthoff A, Brockmeyer NH, et al. Anal carcinoma in human immunodeficiency virus-positive men: results of a prospective study from Germany. *Br J Dermatol*. 2010;162(6):1269-77. DOI 10.1111/j.1365-2133.2010.09712.x.
- w28. Esser S, Kreuter A, Oette M, et al. German-Austrian guidelines on anal dysplasia and anal cancer in HIV-positive individuals: prevention, diagnosis, and treatment. *J Dtsch Dermatol Ges*. 2015;13(12):1302-19. DOI 10.1111/ddg.12726.
- w29. Richel O, Hallensleben NDL, Kreuter A, et al. High-Resolution Anoscopy: Clinical Features of Anal Intraepithelial Neoplasia in HIV-positive Men. *Dis Colon Rectum*. 2013;56(11):1237-42. DOI 10.1097/DCR.0b013e3182a53568.
- w30. Schlecht HP, Fugelso DK, Murphy RK, et al. Frequency of Occult High-Grade Squamous Intraepithelial Neoplasia and Invasive Cancer within Anal Condylomata in Men Who Have Sex with Men. *Clin Infect Dis*. 2010;51(1):107-10. DOI 10.1086/653426.
- w31. Kreuter A, Siorokos C, Oellig F, et al. High-Grade Dysplasia in Anogenital Warts of HIV-Positive Men. *JAMA Dermatol*. 2016. DOI 10.1001/jamadermatol.2016.2503.
- w32. Werner RN, Westfechtel L, Dressler C, et al. Self-administered interventions for anogenital warts in immunocompetent patients: a systematic review and meta-analysis. *Sex Transm Infect*. 2016. DOI 10.1136/sextrans-2016-052768.
- w33. Higgins JPT ; Green S (editors). *Cochrane Handbook for Systematic Reviews of Interventions* Version 5.1.0 [updated March 2011]: The Cochrane Collaboration; 2011 [Available from: <http://handbook.cochrane.org/>].
- w34. Atkins D BD, Briss PA, Eccles M, Falck-Ytter Y, Flottorp S, Guyatt GH, Harbour RT, Haugh MC, Henry D, Hill S, Jaeschke R, Leng G, Liberati A, Magrini N, Mason J, Middleton P, Mrukowicz J, O'Connell D, Oxman AD, Phillips B, Schünemann HJ,

- Edejer T, Varonen H, Vist GE, Williams JW Jr, Zaza S; GRADE Working Group. Grading quality of evidence and strength of recommendations. *BMJ*. 2004;328(7454):1490. DOI 10.1136/bmj.328.7454.1490.
- w35. The Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager (RevMan). Version 5.3.5 ed. Copenhagen 2014.
- w36. Guyatt GH, Oxman AD, Santesso N, et al. GRADE guidelines: 12. Preparing Summary of Findings tables - binary outcomes. *J Clin Epidemiol*. 2014;66(2):158-72. DOI 10.1016/j.jclinepi.2012.01.012.
- w37. Guyatt G, Oxman AD, Akl EA, et al. GRADE guidelines: 1. Introduction - GRADE evidence profiles and summary of findings tables. *J Clin Epidemiol*. 2011;64(4):383-94. DOI 10.1016/j.jclinepi.2010.04.026.
- w38. Higgins JPT, Altman DG, Gøtzsche PC, et al. The Cochrane Collaboration's tool for assessing risk of bias in randomised trials. *BMJ*. 2011;343. DOI 10.1136/bmj.d5928.
- w39. Guyatt G, Oxman AD, Sultan S, et al. GRADE guidelines: 11. Making an overall rating of confidence in effect estimates for a single outcome and for all outcomes. *J Clin Epidemiol*. 2014;66(2):151-7. DOI 10.1016/j.jclinepi.2012.01.006.
- w40. Guyatt GH, Oxman AD, Vist G, et al. GRADE guidelines: 4. Rating the quality of evidence - study limitations (risk of bias). *J Clin Epidemiol*. 2014;64(4):407-15. DOI 10.1016/j.jclinepi.2010.07.017.
- w41. Guyatt GH, Oxman AD, Kunz R, et al. GRADE guidelines: 7. Rating the quality of evidence - inconsistency. *J Clin Epidemiol*. 2014;64(12):1294-302. DOI 10.1016/j.jclinepi.2011.03.017.
- w42. Guyatt GH, Oxman AD, Kunz R, et al. GRADE guidelines: 8. Rating the quality of evidence - indirectness. *J Clin Epidemiol*. 2014;64(12):1303-10. DOI 10.1016/j.jclinepi.2011.04.014.
- w43. Guyatt GH, Oxman AD, Kunz R, et al. GRADE guidelines 6. Rating the quality of evidence - imprecision. *J Clin Epidemiol*. 2014;64(12):1283-93. DOI 10.1016/j.jclinepi.2011.01.012.
- w44. Guyatt GH, Oxman AD, Montori V, et al. GRADE guidelines: 5. Rating the quality of evidence - publication bias. *J Clin Epidemiol*. 2014;64(12):1277-82. DOI 10.1016/j.jclinepi.2011.01.011.